Diabetic Retinopathy - Pipeline Review, H1 2018

  • ID: 4542976
  • Report
  • 219 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Abzena Plc
  • BCN Peptides SA
  • EyeGene Inc
  • Kowa Co Ltd
  • Nemus Bioscience Inc
  • Profarma
  • MORE
Diabetic Retinopathy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H1 2018, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

Report Highlights:

This latest pipeline guide Diabetic Retinopathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 7, 47, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abzena Plc
  • BCN Peptides SA
  • EyeGene Inc
  • Kowa Co Ltd
  • Nemus Bioscience Inc
  • Profarma
  • MORE
Introduction

Diabetic Retinopathy - Overview

Diabetic Retinopathy - Therapeutics Development

Diabetic Retinopathy - Therapeutics Assessment

Diabetic Retinopathy - Companies Involved in Therapeutics Development

Diabetic Retinopathy - Drug Profiles

Diabetic Retinopathy - Dormant Projects

Diabetic Retinopathy - Discontinued Products

Diabetic Retinopathy - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Diabetic Retinopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Diabetic Retinopathy - Pipeline by Abzena Plc, H1 2018

Diabetic Retinopathy - Pipeline by Acucela Inc, H1 2018

Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H1 2018

Diabetic Retinopathy - Pipeline by Applied Therapeutics Inc, H1 2018

Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by BCN Peptides SA, H1 2018

Diabetic Retinopathy - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Diabetic Retinopathy - Pipeline by Charlesson LLC, H1 2018

Diabetic Retinopathy - Pipeline by Coherus BioSciences Inc, H1 2018

Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2018

Diabetic Retinopathy - Pipeline by Dynamis Therapeutics Inc, H1 2018

Diabetic Retinopathy - Pipeline by EyeGene Inc, H1 2018

Diabetic Retinopathy - Pipeline by EyePoint Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Diabetic Retinopathy - Pipeline by Formycon AG, H1 2018

Diabetic Retinopathy - Pipeline by IMMD Inc, H1 2018

Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc, H1 2018

Diabetic Retinopathy - Pipeline by Kowa Co Ltd, H1 2018

Diabetic Retinopathy - Pipeline by Lupin Ltd, H1 2018

Diabetic Retinopathy - Pipeline by M's Science Corp, H1 2018

Diabetic Retinopathy - Pipeline by Mabion SA, H1 2018

Diabetic Retinopathy - Pipeline by Medy-Tox Inc, H1 2018

Diabetic Retinopathy - Pipeline by Nemus Bioscience Inc, H1 2018

Diabetic Retinopathy - Pipeline by NGM Biopharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by Oculis ehf, H1 2018

Diabetic Retinopathy - Pipeline by OcuNexus Therapeutics Inc, H1 2018

Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc, H1 2018

Diabetic Retinopathy - Pipeline by PanOptica Inc, H1 2018

Diabetic Retinopathy - Pipeline by Profarma, H1 2018

Diabetic Retinopathy - Pipeline by Promedior Inc, H1 2018

Diabetic Retinopathy - Pipeline by Protheragen Inc, H1 2018

Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by Rezolute Inc, H1 2018

Diabetic Retinopathy - Pipeline by Ribomic Inc, H1 2018

Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc, H1 2018

Diabetic Retinopathy - Pipeline by Sylentis SAU, H1 2018

Diabetic Retinopathy - Pipeline by ThromboGenics NV, H1 2018

Diabetic Retinopathy - Pipeline by Unity Biotechnology Inc, H1 2018

Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H1 2018

Diabetic Retinopathy - Dormant Projects, H1 2018

Diabetic Retinopathy - Dormant Projects, H1 2018 (Contd..1), H1 2018

Diabetic Retinopathy - Dormant Projects, H1 2018 (Contd..2), H1 2018

Diabetic Retinopathy - Dormant Projects, H1 2018 (Contd..3), H1 2018

Diabetic Retinopathy - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Diabetic Retinopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abzena Plc
  • Acucela Inc
  • Aerie Pharmaceuticals Inc
  • Antisense Therapeutics Ltd
  • Applied Therapeutics Inc
  • Araim Pharmaceuticals Inc
  • BCN Peptides SA
  • Boehringer Ingelheim GmbH
  • Charlesson LLC
  • Coherus BioSciences Inc
  • Crinetics Pharmaceuticals Inc
  • Dimerix Bioscience Pty Ltd
  • Dynamis Therapeutics Inc
  • EyeGene Inc
  • EyePoint Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Formycon AG
  • IMMD Inc
  • Kodiak Sciences Inc
  • Kowa Co Ltd
  • Lupin Ltd
  • M's Science Corp
  • Mabion SA
  • Medy-Tox Inc
  • Nemus Bioscience Inc
  • NGM Biopharmaceuticals Inc
  • Oculis ehf
  • OcuNexus Therapeutics Inc
  • Ohr Pharmaceutical Inc
  • PanOptica Inc
  • Profarma
  • Promedior Inc
  • Protheragen Inc
  • Regeneron Pharmaceuticals Inc
  • Rezolute Inc
  • Ribomic Inc
  • Strongbridge Biopharma plc
  • Sylentis SAU
  • ThromboGenics NV
  • Unity Biotechnology Inc
  • VESSL Therapeutics Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll